News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–43
Matches
43
Sources here
6
Companies here
1
Search results Stored financial headlines

Active search

43 matching headlines

Ticker or company: RPRXMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Earnings Main company 🇺🇸 United States

Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD

Royalty Pharma Plc Class A (HAM:RPD) generated €2.77 billion in revenue last year, primarily from its Biopharmaceutical Royalties segment, which accounted for €2.02 billion. The United States was the largest contributor to this revenue, also bringing in €2.02 billion. This data provides a breakdown …

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sharemaestro News Company research Main company 🇺🇸 United States

Royalty Pharma pushes against Healthcare weakness with a 78-week Trend Signal

RPRX rose 3.1% in a down week for Healthcare and sits just 2.1% below its 52-week high, but volume at 0.7x the 13-week average keeps confirmation less than emphatic.

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Deals and strategy Main company 🇺🇸 United States

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma has acquired a royalty interest in AstraZeneca's cliramitug from Neurimmune for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 TTR-fibril-depleting antibody for TTR amyloidosis with cardiomyopathy (ATTR-CM), a rapidly growing market. This investment targets a significant unmet …

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Earnings Main company 🇺🇸 United States

Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share

Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation …

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders

Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest …

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pluang Earnings Main company 🇺🇸 United States

Royalty Pharma declares $0.235 dividend for Q3 2026, payable September 10

Royalty Pharma plc has declared a dividend of $0.235 per Class A ordinary share for the third quarter of 2026. This dividend is scheduled to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. The announcement highlights the company's consistent …

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sharemaestro News Company research Main company 🇺🇸 United States

Royalty Pharma’s near-high trend weakens as biotechnology peers move faster

RPRX remains in an active weekly Trend Signal and sits 15.4% above its Trend Line, but a 3.5% weekly fall, fading pressure and average volume leave the latest read more balanced than bullish.

RPRX main company
Sharemaestro market context Trend signal active 52 weeks +63.8% · Next-week setup positive 61.4% RPRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context